Comparing of Brainstorm Cell Therapeutics Inc. (BCLI) and Sierra Oncology Inc. (NASDAQ:SRRA)

Both Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Sierra Oncology Inc. (NASDAQ:SRRA) are each other’s competitor in the Biotechnology industry. Thus the compare of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Brainstorm Cell Therapeutics Inc. N/A 0.00 8.29M -0.42 0.00
Sierra Oncology Inc. N/A 0.00 49.65M -0.63 0.00

Demonstrates Brainstorm Cell Therapeutics Inc. and Sierra Oncology Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Brainstorm Cell Therapeutics Inc. 0.00% -101.8% -59.6%
Sierra Oncology Inc. 0.00% -43.8% -40.8%

Risk & Volatility

Brainstorm Cell Therapeutics Inc.’s 1.56 beta indicates that its volatility is 56.00% more volatile than that of S&P 500. Competitively, Sierra Oncology Inc.’s 69.00% volatility makes it more volatile than S&P 500, because of the 1.69 beta.

Liquidity

Brainstorm Cell Therapeutics Inc. has a Current Ratio of 3.3 and a Quick Ratio of 3.3. Competitively, Sierra Oncology Inc.’s Current Ratio is 14.7 and has 14.7 Quick Ratio. Sierra Oncology Inc.’s better ability to pay short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Insider & Institutional Ownership

Roughly 11.8% of Brainstorm Cell Therapeutics Inc. shares are owned by institutional investors while 63.4% of Sierra Oncology Inc. are owned by institutional investors. About 11.2% of Brainstorm Cell Therapeutics Inc.’s share are owned by insiders. On the other hand, insiders owned about 0.96% of Sierra Oncology Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Brainstorm Cell Therapeutics Inc. -3.54% -5.49% -27.36% -34.78% -25.37% -23.47%
Sierra Oncology Inc. -6.75% -8.98% -18.28% -52.35% -46.48% -59.25%

For the past year Brainstorm Cell Therapeutics Inc. was less bearish than Sierra Oncology Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.